Rising JCV-Ab index during natalizumab therapy for MS
نویسندگان
چکیده
منابع مشابه
Rising JCV-Ab index during natalizumab therapy for MS
Infection with JC virus (JCV) is not noticeable and is usually inconsequential. Natalizumab therapy, however, blocks the very late antigen-4 adhesion molecule on immune cells, preventing them from attaching to vascular cell adhesion molecule-1 on brain endothelial cells and then penetrating into the CNS. The dearth of T cells, and perhaps other factors, allows JCV to infect oligodendroglia and ...
متن کاملTherapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
OBJECTIVE The aim of the study was to analyze John Cunningham virus (JCV) serology in natalizumab-treated patients over time and assess whether they are influenced by natalizumab treatment. METHODS German (n = 1,921; 525 longitudinally) and French (n = 1,259; 711 longitudinally) patients were assessed for JCV serology alongside their therapy with natalizumab. RESULTS JCV serostatus changed ...
متن کاملMay baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study
Background: We prospectively assessed the influence of JCVstatus on disability’s accrual in RRMS patients treated with Natalizumab at two tertiary MS centres, settled in Italy. Methods: Negative binomial model was used to assess the influence of baseline JCV status (positive or negative) treatment on clinical and radiological disease activity during the 24 months’ follow-up. Results: One hundre...
متن کاملNatalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated with increased risk of developing progressive multifocal leukoencephalopathy (PML). The evaluation of these conditions has been used to estimate ri...
متن کاملNatalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation
The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leukoencephalopathy (PML). To correlate natalizumab-induced phenotypic modifications of peripheral bl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology - Neuroimmunology Neuroinflammation
سال: 2016
ISSN: 2332-7812
DOI: 10.1212/nxi.0000000000000199